Dmitry Balyasny’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.1M | Buy |
+134,981
| New | +$8.67M | 0.01% | 1053 |
|
|
2026
Q1 | – | Sell |
-18,825
| Closed | -$1.51M | – | 3145 |
|
|
2025
Q4 | $1.51M | Sell |
18,825
-303,348
| -94% | -$20.4M | ﹤0.01% | 2002 |
|
|
2025
Q3 | $15.7M | Buy |
+322,173
| New | +$19.9M | 0.02% | 825 |
|
|
2025
Q1 | – | Sell |
-49,250
| Closed | -$3.85M | – | 2984 |
|
|
2024
Q4 | $3.85M | Buy |
+49,250
| New | +$3.96M | 0.01% | 1400 |
|
|
2024
Q2 | – | Sell |
-90,674
| Closed | -$7.74M | – | 2776 |
|
|
2024
Q1 | $7.74M | Buy |
90,674
+44,728
| +97% | +$3.51M | 0.01% | 1043 |
|
|
2023
Q4 | $3.93M | Buy |
+45,946
| New | +$3.97M | 0.01% | 1208 |
|
|
2023
Q3 | – | Sell |
-54,733
| Closed | -$4.66M | – | 2446 |
|
|
2023
Q2 | $4.66M | Sell |
54,733
-98,229
| -64% | -$8.3M | 0.01% | 1090 |
|
|
2023
Q1 | $12.7M | Buy |
+152,962
| New | +$12.4M | 0.03% | 686 |
|
|
2022
Q4 | – | Sell |
-243,677
| Closed | -$18M | – | 2952 |
|
|
2022
Q3 | $18M | Sell |
243,677
-302,999
| -55% | -$21.8M | 0.06% | 462 |
|
|
2022
Q2 | $35.6M | Buy |
+546,676
| New | +$32.4M | 0.12% | 241 |
|
|
2022
Q1 | – | Sell |
-355,127
| Closed | -$18.8M | – | 2620 |
|
|
2021
Q4 | $18.8M | Buy |
355,127
+14,311
| +4% | +$872K | 0.06% | 435 |
|
|
2021
Q3 | $24.1M | Buy |
340,816
+328,682
| +2,709% | +$20.7M | 0.1% | 280 |
|
|
2021
Q2 | $809K | Buy |
+12,134
| New | +$859K | ﹤0.01% | 1379 |
|
|
2021
Q1 | – | Sell |
-164,944
| Closed | -$19.6M | – | 1891 |
|
|
2020
Q4 | $19.6M | Sell |
164,944
-97,076
| -37% | -$10.5M | 0.11% | 264 |
|
|
2020
Q3 | $22.9M | Buy |
262,020
+135,596
| +107% | +$11.9M | 0.17% | 164 |
|
|
2020
Q2 | $11.3M | Buy |
+126,424
| New | +$12.8M | 0.1% | 305 |
|
|
2020
Q1 | – | Sell |
-175,119
| Closed | -$20.1M | – | 1284 |
|
|
2019
Q4 | $20.1M | Buy |
+175,119
| New | +$21.2M | 0.12% | 259 |
|
|
2019
Q2 | – | Sell |
-8,846
| Closed | -$774K | – | 1573 |
|
|
2019
Q1 | $774K | Buy |
+8,846
| New | +$804K | 0.01% | 1087 |
|
|
2018
Q3 | – | Sell |
-4,953
| Closed | -$444K | – | 1816 |
|
|
2018
Q2 | $444K | Buy |
+4,953
| New | +$418K | ﹤0.01% | 1384 |
|
|
2017
Q4 | – | Sell |
-7,730
| Closed | -$347K | – | 2147 |
|
|
2017
Q3 | $347K | Sell |
7,730
-58,570
| -88% | -$2.43M | ﹤0.01% | 1470 |
|
|
2017
Q2 | $2.62M | Buy |
+66,300
| New | +$2.72M | 0.01% | 885 |
|
Other funds holding HAE
AI
Dmitry Balyasny's HAE Position: Q2 2026 in Review
Dmitry Balyasny opened a new position in Haemonetics (HAE) in Q2 2026: 134,981 shares worth $10.1M. The stake represents 0.01% of the portfolio and ranks #1053 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in HAE as recently as Q4 2025.
Dmitry Balyasny first reported a position in HAE in Q2 2017 and has held it in 21 quarters since. The position peaked at $35.6M in Q2 2022. 327 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Dmitry Balyasny held 134,981 shares of Haemonetics worth $10.1M as of Q2 2026.
- Haemonetics was a new Dmitry Balyasny position in Q2 2026.
- Haemonetics made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1053 holding.
- Dmitry Balyasny first reported a position in Haemonetics in Q2 2017 and has held it in 21 quarters since.
- Dmitry Balyasny's Haemonetics position peaked at $35.6M in Q2 2022.
- 327 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.